PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $65.06M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 0.43M
Average 0.38M
PMVP Long-term Debt
Borrowings due after more than one year.
PMV Pharmaceuticals, Inc.NASDAQ: PMVP
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $0, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 435K USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 435K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Long-term Debt vs competitors
How PMVP compares with its peers on the latest reported figures
- PMVP's Mar 2026 long-term debt of $0 is the 4th highest of the 9 companies compared; the peer median is $0.
- Long-term debt amounts to 0.0% of total assets for PMVP, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $244.12M | +135520.6% | — | 75.3% |
| Mar 2026 | $32.65M | +1.5% | +3.6% | 16.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.26M | — | — | 1.2% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PMVP) | $0 | +67761.0% | +3.6% | 0.0% | |
Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 172.47M | 108.3M | 37.71M | 40.88M | 37.98M |
| Short-term Investments | 124.7M | 132.76M | 165.35M | 128.58M | 74.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 822K | 5.95M | 4.35M | 6.2M | 2.28M |
| Total Current Assets | 301.29M | 247.01M | 207.41M | 175.66M | 115.23M |
| Property, Plant & Equipment (Net) | 13.15M | 20.49M | 19.05M | 1.55M | 1.04M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 16.91M | 2.5M | 25.51M | 13.84M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 221K | 313K | 190K | 235K | 297K |
| Total Non-current Assets | 30.28M | 23.3M | 44.74M | 15.63M | 1.34M |
| Total Assets | 331.57M | 270.31M | 252.15M | 191.29M | 116.56M |
| Account Payables | 3.19M | 3M | 3.24M | 6.58M | 3.16M |
| Short-term Debt | 0 | 0 | 0 | 352K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.8M | 2.9M | 4.5M | 5.01M | 4.53M |
| Total Current Liabilities | 12.22M | 10.83M | 14.03M | 14.37M | 11.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 435K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 10.79M | 13.45M | 12.43M | 838K | 435K |
| Total Liabilities | 23.01M | 24.28M | 26.46M | 15.21M | 11.85M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (167.73M) | (241.04M) | (310M) | (368.71M) | (446.45M) |
| Accumulated OCI | (78K) | (445K) | 224K | 139K | 84K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 308.56M | 246.03M | 225.69M | 176.08M | 104.71M |
| Total Debt | 11.19M | 13.98M | 13.29M | 1.19M | 838K |
| Net Debt | (161.27M) | (94.32M) | (24.42M) | (39.69M) | (37.15M) |
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
Intrinsic Alpha fair value
Locked
Current Price
$1.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.